Table 3.
Efficacy of 177Lu-PSMA therapy in literature.
| Reference Study |
Patient Number |
Response % (RECIST) | Response % (Symptom) | PSA Decline > 50% |
PFS | OS |
|---|---|---|---|---|---|---|
| Hofman [16] | 30 | CR: 40% PR: 37% SD: 37% |
37% | 57% | 7.6 months | 13.5 months |
| Baum [19] | 56 | CR: 20% PR: 52% SD: 28% |
33% | 59% | 13.7 months | - |
| Rahbar [21] | 145 | PR: 45% * SD: 28% * |
- | 45% | - | - |
| Yadav [38] | 90 | PR: 23% SD: 54% PD: 23% |
54% | 45.5% | 11.8 months | 14 months |
| Tagawa [40] | 47 | 10.6% | 3 months | - | ||
| Kim [42] | 455 | - | - | 34.45% | - | - |
| Calopedos [43] | 369 | - | - | 37% | - | - |
| Von Eyben [45] | 669 | - | - | 43% | - | - |
| Bräuer [46] | 59 | - | - | 53% | 4.5 months | 8 months |
| Ahmadzadehfar [47] | 52 | - | - | 44.2% | - | 15 months |
| Kulkarni [48] | 119 | - | - | 57.5% | 10.7 months |
- |
| Ahmadzadehfar [49] | 100 | - | - | 69% | - | 15 months |
| Rahbar [50] | 104 | - | - | 49% | - | 14 months |
| Rahbar [51] | 71 | - | - | 56% | - | - |
| Rahbar [52] | 28 | - | - | 50% | - | 7.3 months |
| Barber [53] | 167 | - | - | 40% ** 57% *** |
6 months ** 8.8 months *** |
10.7 months ** 27.1 months *** |
| Ferdinandius [56] | 40 | - | - | 32.5% | - | - |
| Overall | 28–669 | CR: 20–40% PR: 23–52% SD: 28–54% PD: 23% |
33–54% | 10.6–69% | 3–13.7 months | 7.3–27.1 months |
* Evaluated in 47 patients; ** Taxane-pretreated patients; *** Taxane-naïve patients; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; PFS: Progression free survival; OS: Overall survival; RECIST: Response evaluation criteria in solid tumors; -, not applicable.